Evidence map›Paper›PMID 34030679›Full record

ReviewJournal of biomedical science2021

New therapeutic approaches of mesenchymal stem cells-derived exosomes.

Jana Janockova, Lucia Slovinska, Denisa Harvanova, Timea Spakova, Jan Rosocha

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Journal of biomedical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05787288 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Study on the Safety and Efficacy of Mesenchymal Stem Cell Exosomes in the Treatment of Coronavirus Infection.

TypeinterventionalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2023 to 2025Enrolled240ConditionsCOVID-19 PneumoniaArmsExtracellular Vesicles from Mesenchymal Stem Cells
NCT05808400 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19 Infection

TypeinterventionalSponsorHuazhong University of Science and TechnologyRan2023 to 2025Enrolled80ConditionsLong COVID-19 SyndromeArmsMSC-derived exosomes
3 · Its place in the literature

Who cites it

82 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jana JanockovaAssociated Tissue Bank, Faculty of Medicine, P. J. Safarik University in Kosice, Tr. SNP 1, 04011, Kosice, Slovakia. jana.janockova@gmail.com.ORCID http://orcid.org/0000-0002-2034-1860
Lucia SlovinskaAssociated Tissue Bank, Faculty of Medicine, P. J. Safarik University in Kosice, Tr. SNP 1, 04011, Kosice, Slovakia.
Denisa HarvanovaAssociated Tissue Bank, Faculty of Medicine, P. J. Safarik University in Kosice, Tr. SNP 1, 04011, Kosice, Slovakia.
Timea SpakovaAssociated Tissue Bank, Faculty of Medicine, P. J. Safarik University in Kosice, Tr. SNP 1, 04011, Kosice, Slovakia.
Jan RosochaAssociated Tissue Bank, Faculty of Medicine, P. J. Safarik University in Kosice, Tr. SNP 1, 04011, Kosice, Slovakia.

Funding

OPENMED ITMS2014+: 313011V455
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) have been demonstrated to have a great potential in the treatment of several diseases due to their differentiation and immunomodulatory capabilities and their ability to be easily cultured and manipulated. Recent investigations revealed that their therapeutic effect is largely mediated by the secretion of paracrine factors including exosomes. Exosomes reflect biophysical features of MSCs and are considered more effective than MSCs themselves. Alternative approaches based on MSC-derived exosomes can offer appreciable promise in overcoming the limitations and practical challenges observed in cell-based therapy. Furthermore, MSC-derived exosomes may provide a potent therapeutic strategy for various diseases and are promising candidates for cell-based and cell-free regenerative medicine. This review briefly summarizes the development of MSCs as a treatment for human diseases as well as describes our current knowledge about exosomes: their biogenesis and molecular composition, and how they exert their effects on target cells. Particularly, the therapeutic potential of MSC-derived exosomes in experimental models and recent clinical trials to evaluate their safety and efficacy are summarized in this study. Overall, this paper provides a current overview of exosomes as a new cell-free therapeutic agent.

Indexed as

Cell- and Tissue-Based TherapyCell DifferentiationExosomesHumansImmunomodulationMesenchymal Stem Cell TransplantationRegenerative MedicineCell-free therapyExosomesMesenchymal stem cellsTherapeutic potential

Identifiers

PMID34030679
PMCPMC8143902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.